KEY POINTS
- This prospective veterinary feasibility study evaluated single-fraction stereotactic radiosurgery for spontaneous brain tumors in ten pet dogs with presumed glioma. Five dogs received 10 Gy, five received 15 Gy, and three additional dogs managed without radiation served as a nonrandomized control group. Tumors were diagnosed using MRI and clinical criteria without biopsy confirmation. Treatment was delivered at Grenoble Alpes University Hospital using equipment, imaging, and quality assurance procedures also employed for human radiotherapy.
- SRS was delivered using a conventional 6-MV linac with three to five noncoplanar arcs. The target was defined from MRI, with CTV equal to GTV and an additional 2-mm PTV expansion. A prescription of 10 Gy or 15 Gy was delivered to the 70% isodose line, resulting in approximate central doses of 14.3 Gy and 21.4 Gy, respectively. Image guidance incorporated stereotactic immobilization, thermoplastic masks, and ExacTrac positioning. Treatment and positioning required approximately 15 minutes, without interruptions or technical failures.
- The 10-Gy cohort demonstrated substantial early radiological tumor reduction. Mean tumor volume decreased from approximately 6.8 cm³ before treatment to 1.5 cm³ at three months. Mean relative volume reduction was 57.4% at one month and 74.8% at three months, with decreases observed in all five treated dogs. However, some animals developed subsequent progression, including new abnormalities outside the initially treated region, and only three of the five animals were alive at six months.
- Clinical symptoms and owner-reported quality of life improved temporarily following 10 Gy. Mean owner-assessed quality-of-life scores increased from approximately 7.1 to 8.3 on a ten-point scale during early follow-up. Seizure frequency decreased, with seizure-free intervals reported during the first two months after irradiation. However, seizure control was also influenced by anticonvulsants and corticosteroids, while the small sample prevented robust statistical conclusions about neurological improvement.
- Observed survival was longer in irradiated dogs than in untreated controls, but the comparison was highly confounded. Median survival from diagnosis was 281 days after 10 Gy, 325 days after 15 Gy, and 27 days among three nonirradiated dogs (p<0.005 for the reported comparison). The untreated control group was selected according to owners' decisions rather than random allocation and contained only three animals. Differences in baseline tumor characteristics, supportive treatments, and disease course could therefore have substantially influenced survival.
- The 15-Gy cohort raised concerns about late normal-brain tolerance. Imaging at death suggested radiation-associated brain injury in four of five dogs receiving 15 Gy. Although two animals survived longer than 600 days after diagnosis, the higher dose did not establish a clear survival advantage over 10 Gy. The dose comparison was not randomized, and the higher-dose group lacked the same detailed longitudinal imaging and quality-of-life assessment as the initial cohort.
- The study primarily establishes a reproducible veterinary research platform. All tumors were presumptive gliomas rather than histologically confirmed molecular entities, and the numbers were too small to characterize rare or delayed toxicities reliably. The investigators intended the model as a clinical-reference arm for future studies of spatially fractionated radiotherapy and other experimental techniques. It cannot establish a safe or effective single-fraction dose for human glioblastoma.
CLINICAL TAKEAWAY
Single-fraction linac-based SRS was technically feasible in a veterinary clinical setting, with substantial early tumor shrinkage after 10 Gy in dogs with presumed glioma. Higher-dose treatment raised concerns about radiation-associated brain injury, but the small and nonrandomized groups prevent a reliable dose-response or survival comparison. The main value is as a translational research platform rather than evidence informing human brain tumor radiotherapy.